Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • Hypoxia-inducible factors in disease pathophysiology and therapeutics (Oct 2020)
    • Latency in Infectious Disease (Jul 2020)
    • Immunotherapy in Hematological Cancers (Apr 2020)
    • Big Data's Future in Medicine (Feb 2020)
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • Reparative Immunology (Jul 2019)
    • View all review series ...
  • Viewpoint
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
A human immunodeficiency caused by mutations in the PIK3R1 gene
Marie-Céline Deau, … , Alain Fischer, Sven Kracker
Marie-Céline Deau, … , Alain Fischer, Sven Kracker
Published August 18, 2014
Citation Information: J Clin Invest. 2014;124(9):3923-3928. https://doi.org/10.1172/JCI75746.
View: Text | PDF | Corrigendum
Brief Report

A human immunodeficiency caused by mutations in the PIK3R1 gene

  • Text
  • PDF
Abstract

Recently, patient mutations that activate PI3K signaling have been linked to a primary antibody deficiency. Here, we used whole-exome sequencing and characterized the molecular defects in 4 patients from 3 unrelated families diagnosed with hypogammaglobulinemia and recurrent infections. We identified 2 different heterozygous splice site mutations that affect the same splice site in PIK3R1, which encodes the p85α subunit of PI3K. The resulting deletion of exon 10 produced a shortened p85α protein that lacks part of the PI3K p110-binding domain. The hypothetical loss of p85α-mediated inhibition of p110 activity was supported by elevated phosphorylation of the known downstream signaling kinase AKT in patient T cell blasts. Analysis of patient blood revealed that naive T and memory B cell counts were low, and T cell blasts displayed enhanced activation-induced cell death, which was corrected by addition of the PI3Kδ inhibitor IC87114. Furthermore, B lymphocytes proliferated weakly in response to activation via the B cell receptor and TLR9, indicating a B cell defect. The phenotype exhibited by patients carrying the PIK3R1 splice site mutation is similar to that of patients carrying gain-of-function mutations in PIK3CD. Our results suggest that PI3K activity is tightly regulated in T and B lymphocytes and that various defects in the PI3K-triggered pathway can cause primary immunodeficiencies.

Authors

Marie-Céline Deau, Lucie Heurtier, Pierre Frange, Felipe Suarez, Christine Bole-Feysot, Patrick Nitschke, Marina Cavazzana, Capucine Picard, Anne Durandy, Alain Fischer, Sven Kracker

×

Figure 2

Abundance of p110δ protein, phosphorylation of AKT at Ser473, and increased AICD in T cell blasts from patients.

Options: View larger image (or click on image) Download as PowerPoint
Abundance of p110δ protein, phosphorylation of AKT at Ser473, and increa...
(A) Expression of p110δ, AKT, and GAPDH and phosphorylation of AKT at Ser473 and at Thr308 by Western blotting of cell lysates derived from T cell blasts from P1, P2, and P3 and controls before (Ø) and after (+) stimulation with anti-CD3 antibody. (B) Intracellular staining of phosphorylated AKT at Ser473 in nonstimulated and CD3-activated T cell blasts from patients and controls with or without 10 μM IC87114 inhibitor, measured by flow cytometry. (C) A representative experiment showing the expression of flag-tagged WT p85α, flag-tagged p85αΔ434_475, AKT, and Ku-70 and phosphorylation of AKT at Ser473 by Western blotting of cell lysates derived from NIH3T3 cells 2 days after transfection with the indicated expression vector. (D) Representative AICD experiment with T cell blasts from P1 and the control. The results are expressed as the percentage of apoptotic/dead blasts after OKT3 activation minus the percentage of apoptotic/dead blasts in the absence of stimulation. AICD was analyzed with or without 3 μM IC87114 inhibitor with T cell blasts cultured for 6 days. Similar results were obtained at later time points and for P2 and P3 (data not shown).
Follow JCI:
Copyright © 2021 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts